Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    11981009 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed A Phase II Study of Weekly Docetaxel and Topotecan in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian Cancer
Condition: Ovarian Cancer
Interventions: Drug: Docetaxel;   Drug: Topotecan

Indicates status has not been verified in more than two years